BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11105184)

  • 1. Clinical features of and recent advances in therapy for Fabry disease.
    Brady RO; Schiffmann R
    JAMA; 2000 Dec; 284(21):2771-5. PubMed ID: 11105184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model.
    Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC
    Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: enzyme replacement therapy.
    Bongiorno MR; Pistone G; Aricò M
    J Eur Acad Dermatol Venereol; 2003 Nov; 17(6):676-9. PubMed ID: 14761135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A boy with Fabry disease with the onset at the age of four].
    Liu YP; Huang Y; Wang Q; Wu TF; Ma YY; Li XY; Song JQ; Yang YL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):307-11. PubMed ID: 23591357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy in Fabry disease: clinical implications.
    Breunig F; Knoll A; Wanner C
    Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fabry disease].
    Subran B; Montagner C; London J; Lidove O; Mauhin W
    Rev Prat; 2020 May; 70(5):537-540. PubMed ID: 33058644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anderson-Fabry disease: developments in diagnosis and treatment.
    Mehta AB
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narrative review: Fabry disease.
    Clarke JT
    Ann Intern Med; 2007 Mar; 146(6):425-33. PubMed ID: 17371887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic advances in Fabry disease: The future awaits.
    Kant S; Atta MG
    Biomed Pharmacother; 2020 Nov; 131():110779. PubMed ID: 33152937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for fabry disease: a review of the literature.
    Ruiz de Garibay AP; Solinís MA; Rodríguez-Gascón A
    BioDrugs; 2013 Jun; 27(3):237-46. PubMed ID: 23575647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.